

**Supplementary Table SII Adjusted<sup>a</sup> and weighted<sup>b</sup> mean proportion of cycles (95% confidence interval) resulting in implantation, clinical pregnancy, and live birth in association with urinary oxidative stress biomarkers measures among 305 women undergoing 425 IVF cycles.**

	Implantation	p-value <sup>c</sup>	Clinical pregnancy	p-value <sup>c</sup>	Live birth	p-value <sup>c</sup>
<b>8-iso-PGF<sub>2α</sub></b>						
T1	0.63 (0.53, 0.71)	0.43	0.55 (0.46, 0.64)	0.28	0.47 (0.37, 0.56)	0.51
T2	0.68 (0.58, 0.76)		0.62 (0.53, 0.71)		0.51 (0.42, 0.61)	
T3	0.60 (0.50, 0.69)	0.21	0.53 (0.43, 0.62)	0.17	0.47 (0.37, 0.57)	0.57
<b>F<sub>2</sub>-IsoP-M</b>						
T1	0.67 (0.58, 0.76)	0.75	0.60 (0.51, 0.68)	0.61	0.49 (0.39, 0.58)	0.16
T2	0.65 (0.55, 0.74)		0.63 (0.54, 0.72)		0.59 (0.48, 0.68)	
T3	0.58 (0.48, 0.67)	0.29	0.47 (0.37, 0.57)	0.02	0.38 (0.29, 0.48)	p<0.01

<sup>a</sup>Adjusted for maternal age (continuous), BMI (continuous), smoking (never vs. ever), primary infertility dx (male, female, unexplained), race (white vs. other).

<sup>b</sup>Models were weighted to account for number of cycles with weights assigned using inverse number of cycles.

<sup>c</sup>p-value represents differences compared to the 2<sup>nd</sup> tertile.

Note: 1 woman was excluded due to missing BMI information.

Abbreviations: 8-isoprostane-PGF<sub>2α</sub> (8-iso-PGF<sub>2α</sub>); 8-isoprostane-PGF<sub>2α</sub> metabolite (F<sub>2</sub>-isoP-M); in-vitro fertilization (IVF).